Revolution Medicines reported daraxonrasib produced objective response rates of 47–55% in early cohorts of RAS‑mutant metastatic pancreatic ductal adenocarcinoma (PDAC), outperforming historical chemotherapy benchmarks in small, treatment‑naïve and later‑line groups. The agent, a RAS(ON) multi‑selective tri‑complex inhibitor, showed a manageable safety profile with lower grade ≥3 toxicity rates than conventional chemotherapies. The company is positioning daraxonrasib for a Phase 3 program, with progression‑free survival and overall survival data still immature.